FDA Webview
X
about-us-banner

Pay Per View

Home / Pay Per View

New Claims for Meridian BioSciences illumigene Pertussis Test

[ Price : $8.95]

FDA clears a Meridian Bioscience 510(k) for new claims for its illumigene pertussis molecular amplification test.

Guidance on Biosimilar Sponsor Formal Meetings

[ Price : $8.95]

Federal Register Notice: FDA releases a guidance: Formal Meetings Between the FDA and Biosimilar Biological Product Sponsors or Ap...

Regen BioPharma Gives FDA More Data on HemaXellerate

[ Price : $8.95]

Regen BioPharma submits data and responses to questions posed by FDA regarding its IND for HemaXellerate, a cellular drug designed...

FDA Clears Hikma Plant Corrective Actions

[ Price : $8.95]

FDA says Hikma Pharmaceuticals has sufficiently corrected GMP violations at its Portuguese drug manufacturing facility.

FDA Releases 3 PMR/PMC Backlog Reports

[ Price : $8.95]

FDA posts its fifth, sixth and seventh reports on backlogs in postmarketing reports and commitments.

FDA Designates Avelumab Breakthrough Therapy

[ Price : $8.95]

FDA says that Merck and Pfizers avelumab is a breakthrough therapy for patients with metastatic Merkel cell carcinoma.

3 Topics at PDUFA 6 Reauthorization Meeting

[ Price : $8.95]

FDA makes presentations biomarkers, the benefit/risk framework, and patient-reported outcomes at a PDUFA 6 reauthorization stakeho...

Final Guidance on LDT Oversight Due Next Year: Shuren

[ Price : $8.95]

CDRH director Jeffrey Shuren says his Center intends to finalize early next year its guidance on aFramework for Regulatory Oversig...

AngioDynamics Resolves Warning Letter on NanoKnife System

[ Price : $8.95]

FDA issues AngioDynamics a close-out letter effectively resolving promotional issues raised in a 2011 Warning Letter involving its...

FDA Posts Approved PMAs

[ Price : $8.95]

Federal Register Notice: FDA publishes a list of approved PMAs and their safety and effectiveness summaries.